AI and Proteomics Accelerate VAV1 Molecular Glue Discovery
Researchers at Baylor College of Medicine have developed a computational workflow called GluePlex to identify molecular glues that degrade the VAV1 protein. By combining high-throughput proteomics with AI-based protein folding, the team successfully accelerated the discovery of compounds that could treat blood cancers and autoimmune diseases.
Why it matters
This approach offers a more effective therapeutic strategy by eliminating disease-causing proteins entirely rather than just inhibiting their functions.
Molecular glues act as matchmakers with a destructive streak: They bring disease-linked proteins into contact with the cell’s disposal machinery, marking them for elimination. Now, researchers have combined high-throughput proteomics with artificial intelligence (AI) to discover and optimize molecular glues that degrade VAV1, an immune-cell signaling protein implicated in blood cancers and autoimmune diseases.
The Baylor College of Medicine-led study, “ Leveraging high-throughput proteomics and AI-based protein folding to accelerate VAV1 molecular glue discovery ,” was published in Nature Communications . The team was led by senior and co-corresponding author Jin Wang, PhD, director of Baylor’s Center for NextGen Therapeutics, and first and co-corresponding author Hanfeng Lin, PhD, a postdoctoral researcher in Wang’s laboratory.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in